September 2023 Disclaimer This presentation (together with oral statements made in connection herewith, this "Presentation") is for informational purposes only. This Presentation shall not constitute an offer to sell, or

Disclaimer This presentation (together with oral statements made in

connection herewith, this "Presentation") is for informational purposes only. This Presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in

any states or jurisdictions in which such offer, solicitation or sale would be unlawful. Forward Looking Statements Certain statements included in this Presentation that are not historical facts are forward-looking statements for purposes of the

safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward- looking statements generally are accompanied by words such as "believe," "may," "will,"

"estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem,"

"seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited

to, statements by NewAmsterdam Pharma Company N.V. ("NewAmsterdam" or the "Company") regarding estimates and forecasts of other financial and performance metrics and projections of market opportunity; expectations and timing

related to the success, cost and timing of product development activities, including timing of initiation, completion and data readouts for clinical trials and the potential approval of the Company's product candidate; the timing for enrolling

patients; the timing and forums for announcing data; the size and growth potential of the markets for the Company's product candidate; the therapeutic and curative potential of the Company's product candidate; financing and other

business milestones; the Company's expected cash runway; and the Company's plans for commercialization. These statements are based on various assumptions, whether or not identified in this Presentation, and on the current expectations of

the Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a

prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These

forward- looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to the approval of NewAmsterdam's product

candidate and the timing of expected regulatory and business milestones; whether topline, initial or preliminary results from a particular clinical trial will be predictive of the final results of that trial and whether results of early clinical

trials will be indicative of the results of later clinical trials; ability to negotiate definitive contractual arrangements with potential customers; the impact of competitive product candidates; ability to obtain sufficient supply of materials;

global economic and political conditions, including the Russia-Ukraine conflict; the effects of competition on NewAmsterdam's future business; and those factors discussed in documents filed by the Company with the SEC. Additional risks related

to NewAmsterdam's business include, but are not limited to: uncertainty regarding outcomes of the company's ongoing clinical trials, particularly as they relate to regulatory review and potential approval for its product candidate; risks

associated with the Company's efforts to commercialize a product candidate; the Company's ability to negotiate and enter into definitive agreements on favorable terms, if at all; the impact of competing product candidates on the

Company's business; intellectual property-related claims; the Company's ability to attract and retain qualified personnel; and the Company's ability to continue to source the raw materials for its product candidate, together with

the risks described in the Company's filings made with the U.S. Securities and Exchange Commission from time to time. If any of these risks materialize or NewAmsterdam's assumptions prove incorrect, actual results could differ materially

from the results implied by these forward-looking statements. There may be additional risks that are presently unknown by the Company or that NewAmsterdam currently believes are immaterial that could also cause actual results to differ from those

contained in the forward-looking statements. In addition, forward-looking statements reflect NewAmsterdam's expectations, plans, or forecasts of future events and views as of the date of this Presentation and are quali ed in their

entirety by reference to the cautionary statements herein. NewAmsterdam anticipates that subsequent events and developments will cause the Company's assessments to change. These forward-looking statements should not be relied upon as

representing NewAmsterdam's assessments as of any date subsequent to the date of this Presentation. Accordingly, undue reliance should not be placed upon the forward-looking statements. Neither NewAmsterdam nor any of its affiliates undertakes

any obligation to update these forward-looking statements, except as required by law. Market Data Certain information contained in this Presentation relates to or is based on third-party studies, publications, surveys and NewAmsterdam's own

internal estimates and research. In addition, all of the market data included in this Presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while

NewAmsterdam believes its internal research is reliable, such research has not been verified by any independent source and NewAmsterdam cannot guarantee and makes no representation or warranty, express or implied, as to its accuracy and

completeness. Trademarks This Presentation contains trademarks, service marks, trade names, and copyrights of NewAmsterdam and other companies, which are the property of their respective owners. The use or display of third parties' trademarks,

service marks, trade name or products in this Presentation is not intended to, and does not imply, a relationship with NewAmsterdam or an endorsement or sponsorship by or of NewAmsterdam. Solely for convenience, the trademarks, service marks and

trade names referred to in this Presentation may appear with the TM or SM symbols, but such references are not intended to indicate, in any way, that NewAmsterdam will not assert, to the fullest extent permitted under applicable law, their rights or

the right of the applicable licensor to these trademarks, service marks and trade names. 2

NewAmsterdam is developing oral obicetrapib as CETPi to address major

unmet need in hypercholesterolemia and other cardiometabolic diseases OBICETRAPIB Significant unmet need for oral LDL-lowering therapy as adjunct to Company history: Achievements and statins: 35mm+ patients in US/EU5 are not achieving

LDL-lowering milestones: Mid-'20: Founded after goals despite standard-of-care spin-out from Amgen Expected funding through Simple, oral, once-daily, low dose CETP inhibitor with strong LDL- 2026 including CVOT readout

Jan '21: ~$196M Series A lowering observed through Phase 2b: Ph3 enrollment ~50% LDL-lowering as monotherapy, ~63% in combination with June '22: >$1B European completed for BROOKLYN ezetimibe, observed

on top of high-intensity statins license with Menarini and BROADWAY; PREVAIL on Group (including 142.5M Tolerability data in >800 pts track committed capital + significant st back-end economics, 1 Robust effects on ApoB,

non-HDL-C, HDL-C and Lp(a) Late-stage inflection milestone achieved in 2023) points expected from 2023- Convenient oral format + expected low cost of goods sold (COGS) Nov '22: Nasdaq listing 2026 (including Phase 2

& 3 potentially enables broad market access strategy to address existing clinical readouts and (NAMS) with $328M total unmet need registrational filings) proceeds ($93M from FLAC trust in deSPAC, plus $235M PIPE co-lead by Frazier and

Bain) Pipeline expansion >35M ~63% potential in Alzheimer's $4B+ addressable LDL-lowering disease and diabetes Jun '23: ~$1B market cap global market patient observed in and $424M cash opportunity population Phase 2b

Despite availability of statins, tremendous unmet need remains -

with resurgance of the "lower-is better" paradigm 15 Risk of CV 70 LDL-C death, MI, 55- 70 LDL-C LDL-C stroke goals Male deaths 40- 55 LDL-C removed 10 in 20 LDL-C 2013 5 Female deaths P-value = 0.0001 5 0 0 1 2

3 4 5 Trends in prevalence of high LDL-C in US adults, 2 Year Time post-enrollment (years) NHANES 1999-2018 with history of ASCVD Numerous studies Despite statins, CVD deaths ~75% of ASCVD patients are NOT demonstrate resurgence of are on the rise

at their risk-based LDL-C goal paradigm "lower is better" Sources: Trinity NewAmsterdam Market Research Summary; Trinity quantitative market research with N = 100 PCPs and Cardiologists; Bloomberg Prescription Data; IQVIA Rx Tracker. (1)

Literature review suggesting hypercholesterolemia prevalence of ~94mm in the US (average of He et al. 2020, Mercado et al. 2015, Muntner et al. 2013) and ~137mm in EU5 (average of Gomez-Huelgas et al. 2010, Guallar-Castillon et al. 2012, Tragni et

al. 2012, Grau et al. 2011 (3) 8mm statin-intolerant & 22mm above LDL-C target: Percentage of patients in each category estimated from Trinity quantitative market research and the - percentages were then applied to the estimated 84mm

treated number above. (4) <1mm branded patients: 2020 US prescription data for Repatha, Praluent, and Nexletol/Nexlizet were pulled from the Bloomberg Prescription Data Portal that Trinity subscribes to; assuming 12 scripts/year and 70%

compliance for PCSK9s (based on PCSK9 literature) and 59% compliance for Nex/Nex (based on statin literature) patient volume estimates were derived from the prescription data and extrapolated to the EU5. (5) Gaba P, et. al., Association Between

Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE. Circulation. 2023 Feb 13. doi: 10.1161/CIRCULATIONAHA.122.063399. 4 Deaths in Thousands Cumulative incidence rate

Obicetrapib has potential to solve a substantial unmet medical need in

dyslipidemia (1) (1) 231 million 231 million Adults in US/EU5 with hypercholesterolemia Adults in US/EU5 with hypercholesterolemia <1mm >35mm patients not sufficiently (2) post-statin 84 million addressed by available treatment options Treated

with prescription medication (4) patients treated with current branded options >1mm patients treated with current (3) (3) PCSK9s 8 million 22 million branded options: Statin- Still above Bempedoic acid intolerant LDL-C target 30 million* ~5

million** Bempedoic Acid Patients with US ASCVD patients PCSK9s w/ 55-70mgl/dl residual need 180mg Key factors limiting penetration include product o Payors highly restrict access limitations and market access hurdles THE o Low prescriber enthusiasm

for **Based on estimated from Company's analysis of in new U.S. guidance lowering PROBLEM LDL-C goals to 55 mg/dL for very high-risk patients, which could potentially grow existing TPPs addressable patient population Sources: (1) Literature

review suggesting hypercholesterolemia prevalence of ~94mm in the US (average of He et al. 2020, Mercado et al. 2015, Muntner et al. 2013) and ~137mm in EU5 (average of Gomez-Huelgas et al. 2010, Guallar- Castillon et al. 2012, Tragni et al. 2012,

Grau et al. 2011). (2) Value derived from top-down epidemiology-based market model for obicetrapib; assumptions derived from secondary research / literature and primary market research with 5 US and EU5 physicians and payers.

Currently approved post-statin LDL-lowering products all fall short of

the profile patients need Patients need a drug that Nexletol PCSK9i Oral PCSK9 fits the following profile: (1) (1) Strong Modest Strong Potentially strong, Efficacy but significant food effect Oral, Injectable, Oral, Oral, High Dose High Dose Large

Pill Administration/ 180mg ~140-150mg 30mg API + >100mg snac Low Dose Dose Very High Price, Market Access/ Branded Price, High COGS, Broad Access Pricing Highly Restricted Access Price Limited Access likely high price (High COGS) SNAC technology

Safe, Safety & FDA Label: Safe has previously been observed to have Tendon rupture & gout warning Painful injection site reactions Well-Tolerated Tolerability (2) tolerability concerns Strong Lp(a) lowering, HDL raising has potential

Ancillary Potentially modest Lp(a) None Modest Lp(a) Lowering benefits in Alzheimer's and Benefit(s) Lowering diabetes Note: Novartis' stated price of Inclisiran to be approximate to net prices of PCSK9 mAbs. (1) Lighter shaded region of

bar chart represents the additional potential efficacy for fixed dose combinations with ezetimibe. (2) MK-0616 was observed to have AEs comparable to placebo Phase2b trials 6

~50% LDL-C reduction efficacy would be virtually identical to PCSK9

injectables and is substantially better than other oral therapies Cross trial comparison of LDL-C reduction across different approaches (in %) Anacetrapib Evacetrapib Dalcetrapib Ezetimibe Nexletol Repatha Praluent Leqvio 1 2 3 4 5 6 7 8 100mg 130mg

600mg 10mg 180mg 420mg 150mg 284mg 0 Prior CETP inhibitors Existing oral therapies PCSK9 injectables -7 -10 -15 -17 Nexletol bears -21 FDA label for tendon -20 rupture, gout -25 Ezetimibe is generic -30 -40 -46 -47 -51 -50 -60 -70 The trials

represented were selected due to their shared features that reflect the Phase 3 obicetrapib studies. Selecting trials with shared features allows for a potentially more accurate comparison of the LDL-C lowering results, with factors being considered

such as: a) presence of intensive LDL-lowering therapy including (high intensity) statins and PCSK9 inhibitors, b) patient population - ASCVD or ASCVD risk equivalent patients (including primary hypercholesterolemia and HefH) and c) where

possible, selected studies where LDL-C measured by preparative ultracentrifugation (PUC ) as opposed to Friedewald; noted below are those instances where PUC was not used - this is important because at low LDL-C levels (< 50 mg/dL),

calculated LDL-C by Friedewald is overestimated; certain significant deviations from these parameters are provided in the footnotes. Note: The above trials and data do not represent head-to-head comparisons. Actual results may differ from

expectations. Sources: * Circulation. 2021;144:e564-e593 17065. 1. Bowman, L et al. N Engl J Med 2017. 2. Amirhossein, S et al. Curr Pharmaceutical Design 2016. Meta-analysis - Also included hyperlipidaemia patients. LDL-C measured using

direct assays and Friedewald. 3. de Grooth et al. Circulation 2002. LDL-C measured only using Friedewald and did not require subjects to be on prior statin therapy or present with ASCVD. 4. PI Zetia table 7. refers to; Gagne, C et al. Am J Cardiol

2002. LDL-C measured only using Friedewald. 5. PI Nexletol; study 2. refers to; Goldberg, A et al. JAMA 2019;322(18):1780-1788. LDL-C measured using Friedewald and direct assay for LDL-C <50 mg/dL. 6. DESCARTES study. refers to; Blom, D et al. N

Engl J Med 2014. Also 7 included hyperlipidaemia patients. 7. PI Praluent; study 3. refers to; Kereiakes, D et al. Am Heart J 2015. 8. PI Leqvio; study 1. Refers to; Ray, K. N Engl J Med 2020. % LDL-C change versus baseline

Changes in lipid biomarkers for obicetrapib 10mg monotherapy across

phase 1/2 studies Phase 1 MAD TULIP TA-8995-06 ROSE ROSE2 Japan N=10 per arm N=35 per arm N=13 per arm N=40 per arm N=26 per arm N=26 per arm 0 -10 -20 -24.2 -26.3 -30 -29.6 -29.7 -29.8 -32.7 -35.8 -37.0 -37.5 -40 -41.7 -42.9 -43.5 -44.1 -44.4 -45.8

-46.4 -50 -50.8 -60 LCL-C ApoB Non HDL-C 8 Median % change from baseline

Current cash expected to fund obicetrapib development through several

value-creating milestones 2023 2022 2023 2024 2025 2026 1H 2H 1H 2H 1H 2H 1H 2H 1H 2H Phase 3 BROADWAY Trial Lipid Mono Study BROADWAY Ph3 (HeFH or ASCVD; LDL-C 55 mg/dL; LDL n=2,532) regulatory filing BROOKLYN Ph3 Phase 3 BROOKLYN Trial

Lipid Mono Study (HeFH; LDL-C 70 mg/dL; HeFH; n=354) Obicetrapib MACE Monotherapy PREVAIL CVOT regulatory Phase 3 CVOT PREVAIL Trial Product filing (ASCVD or HeFH; LDL-C 70 mg/dL; (obicetrapib 10mg) n=9,000) Japan Ph2b Phase 2b Japan

Trial (LDL-C 70 mg/dL; n=100) ROSE2 Ph2b LEGEND Ezetimibe FDC Phase 2b ROSE2 Trial (LDL-C 70 mg/dL; n=114) Product Initiation (obicetrapib 10mg + ezetimibe 10mg) FDC Ph3 Enrollment complete Phase 3 FDC Trial (LDL-C 70 mg/dL;

n=XXX) Ph3 readout CVOT readout Alzheimer's Product Phase 2a Alzheimer's Alzheimer's Ph2a Ph2 readout (proprietary Disease Trial dose/formulation (ApoE4 carrier; n=10-15) incorporating obicetrapib) PROJECTED CASH RUNWAY

THROUGH 2026 Numerous catalysts expected throughout 2023 9 Note: Other than as noted, the pipeline represents trials that are currently ongoing. Projections are subject to inherent limitations. Actual results may differ from expectations. The timing

of regulatory submissions is subject to additional discussions with regulators. Neuro- Cardiovascular metabolic

Obicetrapib for Cardiovascular Disease 10

Exceptional LDL goal attainment observed with ezetimibe + obicetrapib

combination, including >87% of patients observed to attain <55 mg/dl LDL-C levels % of patients observed with the following LDL-C levels: <100 mg/dl <70 mg/dl <55 mg/dl 100% 93.5% 88.5% 87.1% 73.1% 66.7% 87.1% 73% of combo recipients

of Obi 10 patients observed to have LDL-C 93.5% observed to have of <55 mg/dL of combo recipients LDL-C of observed to have 70 mg/dL or 42.3% LDL-C lower of <70 mg/dL 16.7% Placebo Obi 10 Obi 10/ Placebo Obi 10 Obi 10/ Placebo Obi 10 Obi 10/

Eze 10 Eze 10 Eze 10 Source: Ballantyne CM, et al. J. of Clinical Lipidology 2023 11 % of on-treatment patients at target

1 2 Lp(a) percent reduction from baseline in ROSE and ROSE2

Lp(a) is emerging as a strong and independent marker of CVD risk and an exciting new CVD drug target ROSE2 ROSE Placebo Obicetrapib 5mg Obicetrapib 10mg Obicetrapib 10mg Obi 10mg / Eze 10mg 10 10 4 0 0 -10 -10 -20 -20 -30 -30 -34 -40 -40 -40 -47 -50

-50 -57 -60 -60 Source: 1. Nicholls SJ, et al. Nat Med 2022;28:1672-1678. 2. Ballantyne CM, et al. J. of Clinical Lipidology 2023 12 Lp(a) % change from baseline (median) Lp(a) % change from baseline (median)

Obicetrapib/ezetimibe observed to lower LDL-C by 63.4% on top of HIS in

ROSE2 LDL-C (mg/dL), on-treatment population Median (min, max) LDL-C levels (mg/dL) at baseline & EoT Placebo Obicetrapib 10 mg Obi 10 / Eze 10 10 Time Placebo Obi 10 mg Obi 10 / Eze 10 0 95.5 100.0 87.0 Baseline -10 (60, 211) (35, 189) (62,

152) -6.4 Median (N=40) (N=26) (N=31) -20 88.0 55.5 39.0 EoT (55, 188) (21, 148) (15, 96) -30 Median (N=36) (N=26) (N=31) -40 -6.4 -43.5 -63.4 % Change from -43.5 (-36.4, 96.7) (-78.4, 22.6) (-83.7, -29.7) -50 Baseline (Median) (N=36) (N=26) (N=31)

-60 % Change from -0.85 -39.20 -59.23 Baseline -70 63.4% (-47.41, -30.99) (-66.75, -51.71) LS mean (95% CI) (-7.75, 6.05) reduction - <0.0001 <0.0001 P-value Source: Ballantyne CM, et al. J. of Clinical Lipidology 2023 13 % change from

ROSE2: Non-HDL-C and ApoB percent change from baseline (Day 84)

Non-HDL-C (mg/dL), on-treatment population ApoB (mg/dL), on-treatment population Placebo Obicetrapib 10 mg Obi 10 / Eze 10 Placebo Obicetrapib 10 mg Obi 10 / Eze 10 10 10 5 0 0 -10 -5.6 -5 -2.1 -20 -10 -30 -15 -20 -40 -37.5 -25 -24.2 -50 -30 -55.6

-60 -35 -34.4 -70 -40 Source: Ballantyne CM, et al. J. of Clinical Lipidology 2023 14 % change from baseline (median) % change from baseline (median)

LDL-P believed to be one of the most robust predictors of

cardiovascular risk Small dense LDL particles are more likely to be trapped in arterial wall than larger-sized LDL particles High LDL-P levels typically signify that a patient has a Low LDL-P confers a lower risk higher proportion of

small dense LDL particles vs. - even in patients with high larger-sized LDL particles LDL-C Low LDL-P, Low LDL-C (n = 1,249) Low LDL-P, High LDL-C (n = 284) High LDL-P confers a higher risk - even in patients with low LDL-C LDL-P is